BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Enrollment Completed for Evofem's 3,200-Subject Global Trial of Amphora® Non-Hormonal Contraceptive Gel


7/23/2013 10:14:22 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, July 23, 2013 /PRNewswire/ -- Evofem is pleased to announce the early completion of enrollment for their 3,200-subject Phase III registration study of Amphora® non-hormonal contraceptive gel.

(Logo: http://photos.prnewswire.com/prnh/20130304/CG70327LOGO)

The global trial compares Amphora to Conceptrol®, the brand name of Nonoxynol-9, and the only spermicidal gel currently approved by the FDA.

"We are very pleased with the progress on the development of Amphora," said Tommy G. Thompson, former US Health and Human Services Secretary and Chairman of the Evofem Board of Directors. "Evofem is committed to providing women around the world with greater contraceptive choice and we expect Amphora to fill a critical gap in the market as an inexpensive, easy-to-use product that is woman-controlled and used only when necessary, on-demand."

The Amphora clinical trial is being conducted by Health Decisions, a leading clinical research organization (CRO). "We are delighted that we could accelerate development of Evofem's Amphora contraceptive," said Health Decisions CEO Michael Rosenberg, MD, MPH. "The same award-winning technology that we used in this study has enabled us to help many other sponsors bring drugs and medical devices to market ahead of projections."

About Evofem

Evofem LLC is a privately held biotechnology company that brings advanced prescription and consumer products to global markets. Through its subsidiaries, Evofem Inc. and Cosmederm Bioscience, Evofem discovers, develops and commercializes prescription and over-the-counter products, in the areas of dermatology, pain management, feminine care, contraception, and the prevention of sexually transmitted infections. In February 2013, Evofem entered into a strategic alliance with WomanCare Global, a nonprofit organization whose mission is to provide access to quality, affordable, women's healthcare products through a sustainable supply chain in over 100 countries, with a particular focus on under-served markets in Africa, Asia, and Latin America. Through this alliance, WomanCare Global provides sales, marketing and global distribution support to Evofem's products.

SOURCE Evofem



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES